Status:
COMPLETED
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
Lead Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Conditions:
Paediatric Thyrotoxicosis
Eligibility:
All Genders
2-16 years
Phase:
PHASE3
Brief Summary
The investigators aim to establish whether biochemical control during anti-thyroid drug therapy in young people with thyrotoxicosis varies depending upon whether a 'block and replace' or 'dose titrati...
Detailed Description
Thyrotoxicosis is an uncommon disorder in childhood and adolescence with a UK incidence around 1 per 100,000 (0-15 years). Most patients with thyrotoxicosis have Graves' disease which develops because...
Eligibility Criteria
Inclusion
- All patients with thyrotoxicosis aged between 2 and 16 years at the time of diagnosis. Thyrotoxicosis will be diagnosed by the paediatrician on the basis of the clinical picture and the biochemistry (suppressed TSH with high thyroid hormone levels).
- Child has consented/assented or consent via parent/guardian has been gained prior to any study specific procedures
Exclusion
- Known toxic adenoma / toxic hyperplasia (germline activating TSHR mutation).
- McCune Albright Syndrome.
- Previous episodes of Thyrotoxicosis..
- Known allergic response to any of the study medication or ingredients as per SmPC.
- Previous participation in this study.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01436994
Start Date
July 1 2004
End Date
November 1 2015
Last Update
September 21 2016
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Aberdeen Children's Hospital
Aberdeen, United Kingdom
2
Birmingham Children's Hospital
Birmingham, United Kingdom
3
Addebrookes Hospital
Cambridge, United Kingdom
4
Wales College of Medicine
Cardiff, United Kingdom